Jiangsu Hansoh Pharma will collaborate with Viela Bio of Gaithersburg, Maryland to develop and commercialize inebilizumab in China in a $220 million agreement that includes upfront and milestone payments, plus royalties. Inebilizumab, Viola's humanized anti-CD19 mAb, produced positive data in US pivotal trials for neuromyelitis optica spectrum disorder, a CNS autoimmune disease. Viela believes the candidate will also prove effective against other inflammation/autoimmune and hematologic malignancy indications. Last month, Hansoh filed for a Hong Kong IPO that is expected to raise between $500 million and $1 billion. More details....
Share this with colleagues:
Original Article: Hansoh In-Licenses China Rights to Anti-CD19 mAb in $220 Million Deal